While the prospect is distressing for any animal enthusiast, it is a stark reality that approximately 6 million canines in the United States are diagnosed with cancer annually. Tragically, this disease stands as the leading cause of mortality in dogs. Nevertheless, there is cause for optimism, as scientific endeavors are actively addressing this challenge.
Emerging research indicates a discernible correlation between specific bacterial populations within the gut microbiota of canines afflicted with cancer and their subsequent survival duration following immunotherapy interventions.
“In human studies, distinct gut microbiome profiles have been associated with treatment outcomes in cancer patients undergoing immunotherapy, suggesting their utility as indicators for diagnosis or prognosis,” the investigators elucidate in their published findings.
Could a comparable phenomenon be observed in veterinary medicine?
A cohort comprising fifty-one canine cancer patients at the Bridge Animal Referral Center in the United States participated in a clinical investigation of a cancer immunotherapy vaccine, which has already demonstrated significant potential.
This innovative vaccine fortifies the canine immune system’s capacity to combat tumor proliferation by impeding the function of two proteins, EGFR and HER2, which are frequently overexpressed in certain neoplastic conditions. The aspiration is that this vaccine will afford dogs diagnosed with cancer an extended period of enhanced quality of life with their families, perhaps even obviating the need for a complete remission.
However, it is crucial to recognize that a dog’s immune system does not operate in isolation; rather, it functions within a complex ecosystem of microorganisms, each possessing its own influence. Decades of scientific inquiry have unequivocally demonstrated that the diverse bacteria, fungi, and other microscopic life residing in the intestinal tract significantly impact an animal’s immune response, both locally within the gut and systemically throughout the body.
By examining rectal swab samples from the dogs at Bridge and meticulously tracking their survival trajectories post-treatment, the research team identified eleven distinct bacterial species that appear to exert an influence on the vaccine’s efficacy.
Four of these bacterial types were found to be associated with a prolonged survival period after therapeutic intervention, while seven were linked to a diminished survival outlook. These observed associations remained consistent irrespective of the animal’s breed or the specific type of cancer diagnosed.
This observation strongly suggests that a dog’s intestinal bacterial composition may play a role in modulating its immune responses, even against cancers that do not originate within the digestive system, such as osteosarcoma (a form of bone malignancy) or hemangiosarcoma (cancer affecting the blood vessels).
The current study did not delve into the specific mechanisms by which these microorganisms might influence clinical outcomes; this represents an avenue for subsequent scientific investigation.
“Our research represents an initial stride towards harnessing the gut microbiome as an instrument for prognostic evaluation and for the therapeutic management of cancer, not only in canines but potentially serving as a valuable paradigm for human treatment strategies as well,” states Natalia Shulzhenko, a specialist in host-microbiota interactions at Oregon State University.
Although this field of inquiry and immunotherapy treatments for canine cancer are in their nascent stages, the preliminary results indicate that microbial interventions, such as probiotic supplementation or fecal microbiota transplantation, could serve as complementary therapies to existing canine cancer vaccines.
“Looking ahead, an analysis of a microbiome swab sample could offer predictive insights into a dog’s potential response to cancer therapy,” Shulzhenko observes.
“This capability empowers pet owners and veterinarians to make more judicious decisions regarding animal care. Furthermore, now that specific bacterial links to survival have been identified, we can pursue strategies to ameliorate a dog’s gut microbiome, thereby enhancing vaccine efficacy and extending the animal’s lifespan.”
